In recent years, the treatment of coronary atherosclerotic heart disease has achieved rapid development. Percutaneous coronary intervention (PCI) has become the first choice of treatment for patients with acute coronary syndrome and stable coronary artery disease. Over the last decade, drug-eluting stents (DESs) have remarkably reduced restenosis and the need for iterance after implantation of metallic stents. However, the implanted permanent metallic endovascular devices in the coronary artery to reestablish the patency of a stenotic artery have inherited pitfalls, including vascular inflammation, restenosis, and stent thrombosis. Bioresorbable scaffolds (BRSs) exhibit a new approach in coronary stent technology. In contrast to DESs, they offer transient scaffolding, thereby safeguarding acute gain and early vessel patency. The aim of this review is to describe the history and provide an update on the status of BRS, present the evidence from the clinical evaluation of BRS, and discuss this innovative technology and prospects for improved interventional cardiology.
introduction
In 1977, Andreas Grüntzig introduced the intervention procedure, percutaneous transluminal coronary angioplasty, which opened new horizons in the treatment of coronary heart disease. [1] This novel technology provides a solution to acute vessel occlusion and preventing recoil. However, the high incidence of restenosis and the risk of acute occlusion caused by neointimal hyperplasia and elastic recoil still limited its application. Bare-metal stents (BMSs) are considered the second innovation in interventional cardiology. [2] [3] [4] [5] [6] Although the presence of metal stents can improve late luminal enlargement and vascular remodeling compared with balloon dilatation, the restenosis is not eliminated due to neointimal hyperplasia. [7] [8] [9] Drug-eluting stents (DESs) are considered the third revolution in the history of interventional cardiology. DES is developed in an attempt to decrease the incidence of restenosis. DES can markedly lessen the target lesion revascularization (TLR) and restenosis rates as compared with BMS. [10, 11] However, the thrombosis of stents is still a big problem. [12] [13] [14] The fourth revolution in the history of interventional cardiology resulted from the attempt to improve the limitation of "metallic cages" by insteading it with bioresorbable scaffolds (BRSs). [15, 16] The history of coronary artery intervention is shown in Figure 1 .
The majority of BRS are manufactured from poly-L-lactic acid (PLLA) but can also be made from poly-salicylic acid, tyrosine polycarbonate, and metals. The designs have the ability to allow the restoration of vascular physiology and integrity as they provide temporary scaffolds necessary to sustain the patency of the vessel after coronary intervention, and then gradually dissolve, liberating the vessel from its cages. [17, 18] The potential advantages have led to a movement toward the development of several types of BRS. Hence, a numerous scaffolds are available today with different compositions. Some are in development, some in the preclinical study, while others have already been implanted in patients. The aim of this review is to describe the history of BRS, provide an update, and present evidence from clinical evaluations.
currEntly availablE biorEsorbablE scaffolds
At present, only Igaki-Tamai Stent, Abbott BRS, and DESolve have acquired the certificate Conformite Europeenne (CE)
The pioneering Igaki-Tamai stent
The Igaki-Tamai stent (Kyoto Medical Planning Co, Ltd, Kyoto, Japan), nondrug-eluting, is the first full BRS to undergo evaluation in patients. [19] The device degrades over 18-24 months and mounts on a standard angioplasty balloon. The self-expansion occurs following the use of heated contrast, up to 70°C in the delivery balloon, while the final self-expansion of the stent happens at 37°C in the 20-30 min after stent deployment.
The First-in-HUMAN (FIM) study of the stent (including 15 patients, 19 lesions, and 25 stents) illustrated no major adverse cardiovascular events (MACE) or stent thrombosis events within 30 days, and one repeat percutaneous coronary intervention (PCI) at 6-month follow-up. [20] The late loss and acute gain ratio (loss index) was 0.48. Intravascular ultrasound (IVUS) imaging showed no remarkable stent recoil at day 1, and continued stent expansion was observed in the first 3 months of follow-up. [19, 21] The favorable long-term clinical results of Igaki-Tamai stent were reported at 1-, 3-, 5-and 10-year follow-up, which currently represented the longest available evaluation of BRS. [22] 
Abbott bioresorbable scaffolds
The drug-eluting BRS, Abbott BRS (Abbott Vascular, CA, USA) is currently undergoing clinical trials. [23] ABSORB: Clinical Trial Program in the world is illustrated in Figure 3 . The BRS has backbones of PLLA and coats with a thin layer and an 8.2 μg/mm of antiproliferative drug everolimus. [24] The first BRS of Abbott has a crossing profile of 1.4 mm and a strut thickness of 150 μm, which is designed as out-of-phase zigzag hoops. The stent must be stored in <−20°C to inhibit the physical aging of the polymer and to ensure material stability. During the study of this BRS, safety and feasibility were evaluated in 30 low-risk patients with de novo coronary lesions. Multimodality intravascular imaging was observed at 6-month and 2-year follow-up. Besides, one ischemic-driven major adverse event at 6 months, the study suggested that BRS was clinically safe, and no further MACE occurred in the subsequent 42-month follow-up. [25] Angiographic follow-up at 6 months manifested a late loss of 0.44 mm, which was prominently higher than Xience V EES (0.11 mm). [26] The total number of apparent struts was reduced by 35% over 2 years. [27] The second-generation device (revision 1.1) has a new frame in phase zigzag hoops linked by bridges, which allows for more persistent drug application, uniform strut distribution, and vessel wall support. [28] [29] [30] From a practical perspective, this stent could be stored at room temperature. Forty-five patients underwent angiographic follow-up at ½ year, while the remaining 56 patients experienced invasive imaging at 1 and 3 years. At present, data from the 6-month follow-up of the first cohort indicated late loss was remarkably lower than the revision 1.1. [31] Moreover, it was different from the first generation of BRS, which suggested a more delayed loss of mechanical integrity in compared with the BRS. [32] DeSolve bioresorbable scaffolds DeSolve BRS (Elixir Medical, CA, USA) is a fully bioresorbable polymer (PLLA-based) scaffold, which coats with a PLLA-based resorbable polymer-drug matrix. DeSolve BRS contains two antiproliferative drugs (novolimus at a dose of 5 mcg/mm and myolimus at a dose of 3 mcg/mm). [33] This device was evaluated for the first time in patients in the DeSolve study. Fifteen patients were enrolled in this feasibility trial and underwent PCI with DeSolve BRS. Preliminary follow-up imaging data have shown low neointimal hyperplasia and no evidence of scaffold shrinkage. [34] In addition, the DeSolve study aimed to evaluate the safety and effectiveness of the BRS in 150 patients. [35] Plans are underway to conduct the DeSolve BRS pivotal trial to examine the safety and efficacy of the device in a broad number of human subjects in an effort to obtain CE mark approval.
ART18AZ bioresorbable scaffolds
The ART18AZ BRS (Arterial Remodeling Technologies, Noisy leRoi, France) is made from a PLLA amorphous polymer. This stent does not have drug elution and can provide vessel-transient scaffolding for 5-7 months. The performance of the ART18AZ BRS was compared to the Multilink BMS (Abbott Vascular, Santa Clara, CA, USA) in porcine and rabbit models. More than 250 devices were implanted in models with no MACE reported. [36, 37] The late lumen loss (LLL) was higher in the ART18AZ group in the 1 st week. Thereafter, it began to reduce due to a "positive BRS remodeling" and at 3 months, the LLL in the ART18AZ scaffold was comparable to that observed in the Multilink BMS. [33] In view of these promising results, the company is currently preparing the FIM study to evaluate the safety and feasibility of this device in human trials.
Reva and Rezolve bioresorbable scaffolds
The Reva BRS (Reva Medical Inc, San Diego, CA, USA) is a tyrosine polycarbonate radiopaque stent. The first revision has a unique slide and locking design provides flexibility and strength, eliminated the device hinge points, and maintains the acute lumen gain after device deployment. [38] The resorption process is completed between 18 and 24 months. [38] This device was examined extensively in animal models with promising initial results. [39] The company proceeded to prepare the first human trials which included 27 patients). Follow-up intravascular imaging showed the absence of vessel shrinkage (external elastic lamina: 15.5 ± 4.0 mm 2 at baseline and 15.3 ± 3.1 mm 2 at follow-up). At 12 months, there was a high event rate with 18 reported TLR, 3 of which led to a non-Q-wave MI (myocardial infarction). Subsequently, the second-generation BRS was developed. The ReZolve device has a stronger resilient polymer, a new slide and spiral lock mechanism provides better radial support and decreased vessel recoil. [40] The new scaffold has a better crossing profile, which can be implanted with the use of a 6F guide catheter. After successful preclinical evaluation, the Rezolve BRS is experiencing clinical assessment with the RESTORE trial.
Ideal bioresorbable scaffolds
The Ideal BRS (Xenogenics Corp, Canton, MA, USA) has two components: the backbone and the drug layer. The former is manufactured from polylactide anhydride mixed with a sebacic acid and a polymer of salicylic acid. [41, 42] The latter is composed of salicylate that regulates the release of the antiproliferative drug sirolimus. The presence of salicylic acid provides this stent with anti-inflammatory capabilities. [42] The efficacy and safety of the scaffold were tested in humans in the WHISPER study. Although there was no scaffold shrinkage, there was a decrease in lumen area due to deficient neointima inhibition, which was attributed to inadequate drug dosing and the rapid release of drug elution. [41] Figure 3: ABSORB clinical trial program in the world. ABSORB Cohort A, n = 30; ABSORB Cohort B, n = 101; ABSORB Cohort Extend, n = 814; ABSORB II, n = 501; ABSORB Physiology, n = 35; ABSORB First, n = 1800; ABSORB III, n = 2250; ABSORB Japan, n = 400; ABSORB China, n = 480; ABSORB IV, n = 3000; ABSORB UK Registry, n = 1000
Absorbable metal stent
Absorbable metal stent (AMS) ( Biotronik, Berlin, Germany) consists of magnesium, which is the only bioresorbable metallic stent implanted in patients. This device has a higher mechanical strength and similar properties to other metallic stents. Experimental studies suggest the device has antithrombotic effects attributable to an electronegative charge produced during degradation of this device. The majority of the resorption process can be completed within 2 months and produce inorganic salt without inducing the inflammatory responses. [38, 43, 44] The efficacy and feasibility of the first-generation AMS (AMS 1) was evaluated by the PROGRESS AMS trial. Sixty-three patients were enrolled. There was a higher incidence of TLR at 12 months and an added LLL on angiogram performed at 4 months follow-up. [44] IVUS at 4-month follow-up revealed almost complete resorption of this device and a marked decrease in luminal dimension. Thus, the AMS 1 is improved using a different magnesium alloy, which can provide increased radial strength and a prolonged duration of the resorption process. Preclinical evaluation in animal models validated the effectiveness of the second-generation AMS (AMS 2). [43] Before being implanted in patients, the device underwent further modification with the incorporation of paclitaxel elution and biodegradable matrix (AMS 3). [38] The AMS 3 was evaluated in a clinical setting in the BIOSOLVE study. The TLR rate at 6 months was 4.3%., no other cardiac events occurred. [45] Amaranth bioresorbable scaffolds Amaranth (Amaranth Medical Inc, Mountain View, CA, USA) consists of PLLA polymer and does not include antiproliferative drug. [16] The resorption process requires 1-2 years. This device recently underwent clinical evaluation. Preliminary results found the Amaranth BRS had radial strength and excellent deliverability postdeployment. The LLL at 1-, 3-, and 6-month follow-up in animals receiving Amaranth BRS was similar in animals implanted with the Liberte BMS. In addition, the neointima proliferation was smaller in Amaranth BRS compared to the Liberte BMS. This company is preparing to start the FIM trial.
Xinsorb bioresorbable scaffolds
Xinsorb BRS (Huaan Biotechnology Group, Laiwu, China) is manufactured from PLLA and covered by sirolimus elution. [46] The safety and efficacy of this stent had been examined in a preclinical setting, as compared with the Excel DES (JW Medical System, Weihai, China). [47] A small study reported that 16 BRS and 16 metallic stents were implanted in the porcine artery. No difference in the percent area stenosis or in the inflammation score was found at 30 and 90 days follow-up. [48] Although the preliminary data are promising, further preclinical evaluation is necessary before conducting the FIM trial.
NeoVas bioresorbable scaffolds
The NeoVas BRS (Lepu Medical, Beijing, China) is made from poly(d, l-lactic acid) and covered by rapamycin. The safety and efficacy of this stent was assessed in humans in the ABSORB Cohort A study. In this single-arm, prospective, open-label study, 30 patients with single de novo coronary artery disease and stable or unstable angina were enrolled. IVUS examination at 6 months revealed the average neointimal area was 0.33 mm 2 . The TLR rate at 6 months was 3.98%. The study provides the validity and evidence for promising safety and efficacy of this device.
currEnt problEms of biorEsorbablE scaffolds
Within the field of the percutaneous interventional cardiology, PCI with full BRS has recently attracted great interest in clinical studies. [47, 49] BRS provides extraordinary mechanical sustainability to the vessel wall then dissolves. The new design concept has potential to avoid many of the clinical safety problems connected with DES. [50] Based on data from preclinical and clinical trials, iron-based BRS are promising stents for clinical application. However, due to the long bioresorption time of this device, clinical investigations of the iron stent had not yet been conducted. Magnesium has advantageous biological and mechanical properties to be used for fully bioresorbable vascular scaffolds. The preclinical testing on first-generation metal scaffolds showed magnesium-based absorbable scaffolds had safety and efficacy; however, the clinical effect is still limited.
Due to heterogeneity, patient populations, and reported outcomes, meta-analysis of data has not been conducted because only one small study had been published on the topic of efficacy and safety of BRS. Thus, the majority of the available results were limited by their observational time. In addition, the bulk of the studies were single-arm cohort studies or registries.
thE futurE of biorEsorbablE scaffolds
Theoretically, the current nature of BRS provides an exquisite solution to known limitations of eternal stent implantation. Although available data are minimal, recent results are promising. Clinical trials have demonstrated that BRS can allow the narrowed vessel to restore its normal blood flow. Moreover, BRS can resume vascular function to normal physiology.
It is also anticipated that the large-scale application of BRS will notably keep down the dual-antiplatelet therapy time and improve the risk of late thrombotic stent event connected with eternal scaffolds. In the future, more research is needed to optimize the BRS material design. If successful, a bulk of target lesion vessels will restore their vascular function to normal physiological after vascular restoration treatment using BRS.
More clinical studies are needed to optimize the rate of full reendothelialization to promote lesion vessel healing. Animal models revealed the reendothelialization of BRS could be ended within 1 month. However, based on clinical data from DES, it was shown that the consistent release of antiproliferative drug would defer or even restrain the formation of a complete endothelial monolayer. The vascular healing process is complex and may differ from patient to patient. It is essential to design BRS products with different materials, or combination of different materials, to meet different requirements.
BRS offers the promise of a combination of local drug delivery, radiation, and genetic transfer where tissue specificity and high local drug release could provide an alternative to conventional therapies. Finally, it is hoped that BRS will expand beyond coronary artery to peripheral vascular use in the future.
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